BCI
VKTX icon

Brinker Capital Investments’s Viking Therapeutics VKTX Stock Holding History

Brinker Capital Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,772
Closed -$492K – 1916
2024
Q3 		$492K Buy
+7,772
New +$456K ﹤0.01% 1344
2023
Q1 		– Sell
-10,055
Closed -$94.5K – 1651
2022
Q4 		$94.5K Buy
+10,055
New +$44.9K ﹤0.01% 1317
2021
Q4 		– Sell
-33,649
Closed -$202K – 1443
2021
Q3 		$202K Hold
33,649
– – ﹤0.01% 1259
2021
Q2 		$202K Buy
33,649
+1,811
+6% +$10.8K ﹤0.01% 1311
2021
Q1 		$201K Sell
31,838
-31,136
-49% -$219K ﹤0.01% 1153
2020
Q4 		$355K Buy
62,974
+31,059
+97% +$188K 0.01% 904
2020
Q3 		$186K Buy
+31,915
New +$220K ﹤0.01% 1115

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brinker Capital Investments's VKTX Position: Q4 2024 in Review

Brinker Capital Investments sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 7,772 shares — an estimated $492K sold.

Brinker Capital Investments first reported a position in VKTX in Q3 2020 and held it in 7 quarters. The position peaked at $492K in Q3 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Brinker Capital Investments reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Brinker Capital Investments sold 7,772 Viking Therapeutics shares in Q4 2024, an estimated $492K.
  • Brinker Capital Investments first reported a position in Viking Therapeutics in Q3 2020 and held it in 7 quarters.
  • Brinker Capital Investments's Viking Therapeutics position peaked at $492K in Q3 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Brinker Capital Investments's 13F filing for Q4 2024, filed 1 Aug 2025.